Bharti Devi

Bharti Devi

Auto-generated profile, based on publicly available information

Bharti Devi

Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Central University of Punjab, Bathinda, 151401, India; Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, 151401, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
KJKailash Jangid
Kailash Jangid
BDBharti Devi
Bharti Devi
ASAshrulochan Sahoo
Ashrulochan Sahoo
VKVijay Kumar
Vijay Kumar
ADAshish Ranjan Dwivedi
Ashish Ranjan Dwivedi
VKVinod Kumar
Vinod Kumar
Alzheimer’s disease (AD) is a multifactorial neurological disorder characterized by memory loss and cognitive impairment. The currently available single-targeting drugs have miserably failed in the treatment of AD, and multi-target directed ligands (MTDLs) are being explored as an alternative treatment strategy. Cholinesterase and monoamine oxidase enzymes are reported to play a crucial role in the pathology of AD, and multipotent ligands targeting these two enzymes simultaneously are under various phases of design and development. Recent studies have revealed that computational approaches are robust and trusted tools for identifying novel therapeutics. The current research work is focused on the development of potential multi-target directed ligands that simultaneously inhibit acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) enzymes employing a structure-based virtual screening (SBVS) approach. The ASINEX database was screened after applying pan assay interference and drug-likeness filter to identify novel molecules using three docking precision criteria; High Throughput Virtual Screening (HTVS), Standard Precision (SP), and Extra Precision (XP). Additionally, binding free energy calculations, ADME, and molecular dynamic simulations were employed to get structural insights into the mechanism of protein-ligand binding and pharmacokinetic properties. Three lead molecules viz. AOP19078710, BAS00314308 and BDD26909696 were successfully identified with binding scores of −10.565, −10.543 & −8.066 kcal/mol against AChE and −11.019, −12.357 & −10.068 kcal/mol against MAO-B, better score as compared to the standard inhibitors. In the near future, these molecules will be synthesized and evaluated through in vitro and in vivo assays for their inhibition potential against AChE and MAO-B enzymes.

15 July 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
KJKailash Jangid
Kailash Jangid
BDBharti Devi
Bharti Devi
NKNaveen Kumar
Naveen Kumar
SUShubham Upadhayay
Shubham Upadhayay
VKVinay Kumar
Vinay Kumar
VKVinod Kumar
Vinod Kumar

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
KJKailash Jangid
Kailash Jangid
BDBharti Devi
Bharti Devi
VKVijay Kumar
Vijay Kumar
VKVinod Kumar
Vinod Kumar
Background: Alzheimer’s disease (AD) is a neurological disorder, and its etiology is not completely known. Due to its multifactorial nature different theories were proposed for its initiation and progression including amyloid cascade hypothesis; tau hypothesis; cholinergic hypothesis, excitotoxicity hypothesis, mitochondrial cascade hypothesis. Various attempts are made, aimed to intervene with different target sites including amyloid‐β peptide (Aβ), acetylcholinesterase (AChE), tau protein, monoamine oxidase (MAO), β ‐site amyloid‐Precursor protein‐cleaving Enzyme 1 (BACE‐1), free radicals and metal ions (Fe2+, Cu2+, Zn2+), in order to control the AD. Previously approved drugs are based on the one drug one biological target strategy but over the past several years multi‐target directed ligands (MTDL) strategy has gained much interest in the development of effective inhibitors for the treatment of AD.Method: Based on our previous research work on MTDLs, in the current work we report the synthesis of phenyl‐styryl‐pyrimidine derivatives designed by taking pharmacophore from previously reported molecules and evaluated the effect of extended conjugation in pyrimidine functionalization against MAO‐B and AChE inhibition. In vitro Screening of the synthesized compounds as inhibitors of the cholinesterases and MAO enzymes using Ellman’s and Amplex red assay. This study is also supported by computational tools like‐ molecular docking, molecular dynamics, pharmacokinetics properties etc.Result: Compound VKB‐3 was found to be the most potent MAO‐B inhibitor with an IC50 value of 4.93 μM. Additionally, it exhibits strong inhibition of AChE, with an IC50 value of 9.016 µM. Similarly, compound VKB‐14, displayed inhibition for MAO‐B with an IC50 of 7.265 µM and for AChE with an IC50 of 9.291 µM. In the Lineweaver‐Burk reciprocal plots, both VKB ‐3 and VKB ‐14 exhibited hyperbolic non‐competitive type inhibition. In the docking studies, VKB‐3 and VKB‐14 displayed good affinity towards AChE (‐7.095 and ‐6.767 kcal/mol) and MAO‐B (‐8.548 and ‐11.20 kcal/mol), respectively. MD simulation study suggested that the compound VKB‐14 was able to form more stable complex with both the targeted proteins.Conclusion: VKB‐14 was found as potential lead, which showed good inhibition against both AChE and MAO‐B enzymes. It can be further optimized as MTDL for the treatment of AD.